Abstract: The present invention relates to an ?-helical cell-penetrating peptide multimer, a preparation method thereof and the use thereof, and more particularly, to a peptide multimer comprising a plurality of amphipathic peptides, a method for preparing the peptide multimer, a composition for preventing or treating HIV, which comprises the peptide multimer as an active ingredient, and a composition for intracellular delivery of a biologically active substance, which comprises the peptide multimer and the biologically active substance.

Abstract: This invention relates to collagen-binding synthetic peptidoglycans. More particularly, this invention relates to collagen-binding synthetic peptidoglycans for use in vascular intervention procedures. The invention also relates to kits comprising such collagen-binding synthetic peptidoglycans and catheters or stents.

Abstract: A vaccine composition comprising a fusion protein for inducing enhanced pathogen antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein; (b) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, 2, 3, or 6, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and (c) an antigen of a pathogen, located at the C-terminus of the translocation peptide; (d) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 13; and (e) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein.

Abstract: This document provides methods and materials for producing immune responses against hepatitis B viruses. For example, polypeptides, nucleic acid molecules encoding such polypeptides, virus-like particles containing such polypeptides, vaccine preparations containing one or more polypeptides provided herein, vaccine preparations containing one or more nucleic acid molecules provided herein, vaccine preparations containing one or more virus-like particles provided herein, and methods for inducing immune responses against hepatitis B viruses within mammals (e.g., humans) are provided.

Abstract: Compositions for characterization of Botulinum toxin (BoNT) are described that include a genetically modified cell that is transfected with an artificial construct comprising a nucleic acid sequence that encodes for a hybrid protein having (a) a reporter-containing portion chemically coupled to (b) a cleavage site and (c) a control fluorophore. The cleavage site interacts with a BoNT in a manner that cleaves the reporter-containing portion from remainder of the construct. The cleaved portion is destroyed or otherwise degraded by the local environment, and presence of BoNT is evidenced by reduction in signal from the reporter. The cleavage sequence is all or part of a SNARE protein, the cleavable reporter-containing portion is preferably Yellow Fluorescent Protein (YFP), Citrine, Venus, or a YPet protein and the control fluorophore is preferably CFP, mStrawberry, or a mCherry protein.

Abstract: Described herein are isolated polynucleotides that encode a fluorescent protein which is at least 80% sequence identical to a protein selected from the group consisting of SEQ. ID. NOS: 2, 4, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 46, 50, 54, 58, 62, 66, 70, and 74. Also described are expression constructs containing the polynucleotides, transformed host cells containing the expression constructions, the encoded fluorescent proteins themselves, and methods of using the nucleotides and encoded fluorescent proteins for bioanalytical research.

Abstract: The present invention provides a novel CXCL12-?2 locked dimer polypeptide, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.

Abstract: The present invention relates to interleukin-2 fusion proteins. More specifically, the invention provides, in part, fusion proteins that include a interleukin-2 protein moiety joined to a Bcl-2 family member protein moiety.

Abstract: The novel insulin derivates delivers, after administration to humans, insulin as a function of the glucose concentration in the tissue.

Abstract: The present invention provides a chimeric molecule comprising a VWF protein fused to a heterologous moiety via a VWF linker. The invention provides an efficient VWF linker that can be cleaved in the presence of thrombin. The chimeric molecule can further comprise a polypeptide chain comprising a FVIII protein and a second heterologous moiety, wherein the chain comprising the VWF protein and the chain comprising the FVIII protein are associated with each other. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.

Abstract: The invention relates to synthetic liver-specific promoters and expression constructs for producing polypeptides and functional nucleic acids in the liver of a subject. The invention further relates to Factor VIII proteins containing modifications in the amino acid sequence of the Factor VIII protein, as well as nucleic acid constructs encoding the Factor VIII proteins and methods of using these compositions to treat a bleeding disorder.

Abstract: A modified Ac-TMP-2 protein lacks one or a plurality of acidic C-terminal amino acids normally present in a full-length or wild-type Ac-TMP-2 protein and may also lack one or a plurality of N-terminal amino acids while retaining the amino acid sequence C—S—C at or near the N-terminus. The modified Ac-TMP-2 protein may be useful in method and composition for reducing or alleviating inflammation in a subject. Inflammation may be associated with a disease is a disease of the digestive tract such as chronic gastritis or an inflammatory bowel disease such as Crohn's disease or ulcerative colitis, or a disease of the respiratory system, such as asthma, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease.

Abstract: Genetically modified non-human animals are provided that comprise an immunoglobulin heavy chain locus comprising an unrearranged human heavy chain variable region nucleotide sequence comprising an addition of at least one histidine codon or a substitution of at least one endogenous non-histidine codon with a histidine codon. Compositions and methods for making the genetically modified non-human animals as described herein are provided. Non-human animals capable of expressing an antigen-binding protein characterized by pH-dependent antigen binding, enhanced recyclability and/or enhanced serum half-life are also provided.

Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.

Abstract: One nonexclusive aspect provides molecules further improved from antibodies that can bind to antigens in an ion concentration-dependent manner. An alternative nonexclusive aspect provides safe and more advantageous Fc region variants that have decreased binding to pre-existing ADA. An alternative nonexclusive aspect provides novel IL-8 antibodies that are superior as pharmaceuticals.

Abstract: Monoclonal antibodies against LRP6 and that block the Wnt signaling pathway are disclosed. Methods of production and use thereof are also disclosed.

Abstract: This present invention relates to compounds (e.g., TM4SF1 binding proteins, e.g., anti-TM4SF1 antibodies) that specifically bind to a polypeptide at an epitope including an amino acid sequence of SEQ ID NO: 1. In particular, the compounds of the invention are capable of being internalized into a TM4SF1-expressing cell (e.g., a tumor cell or an angiogenic vasculature endothelial cell) following binding to the epitope of including the amino acid sequence of SEQ ID NO: 1. The invention also provides methods of treating a subject having a disorder associated with pathological angiogenesis with the compounds of the invention.

Abstract: The present disclosure provides antibodies specific for an epitope present on CD22. The antibodies are useful in various treatment, diagnostic, and monitoring applications, which are also provided.

Abstract: The methods, compositions, and assays described herein are based, in part, on the discovery that CD1a mediates inflammation related to certain conditions such as urushiol exposure, psoriasis and other inflammatory skin diseases. One aspect provided herein relates to a method for treating or preventing an inflammatory skin disease, the method comprising: administering a therapeutically effective amount of an inhibitor of CD 1a to a subject having an inflammatory skin disease, thereby treating or preventing the inflammatory skin diseases.

Abstract: The present invention relates to compositions and methods of engineered IgG Fc constructs, wherein said Fc constructs include one or more Fc domains.

Abstract: A method of treating disorder or condition that relates to intracellular signal transmission of a neurotransmitter, comprising administration of an homeopathically potentized form of antibodies to an antigen, which antigen is a molecule capable of effecting the intracellular signal transmission of a neuroreceptor, in particular dopamine or serotonin.

Abstract: It is intended to provide a method for efficiently and stably producing a heteromultimer by incubating, under a reducing condition, homo variants of plural types of polypeptides in which the alteration of amino acids that form the interface between Fc regions and/or the alteration to destabilize the stability of a heavy chain CH3 region has been introduced in the heavy chain CH3 regions so at to achieve the promotion of the dissociation of the Fc regions and/or the control of the association thereof through the use of charge repulsion.

Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.

Abstract: The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.

Abstract: Disclosed are high affinity antibodies or antigen binding fragments thereof, which bind an epitope that lies within the C terminal region of oncofetal antigen (OFA)/immature laminin receptor protein (iLRP), and which do not substantially cross-react with mature OFA/LRP. The antibodies may be conjugated to cytotoxic moieties to enhance their therapeutic efficacy. Methods of making the antibodies and therapeutic and diagnostic uses thereof are also disclosed.

Abstract: Described herein is the use of rabbit hybridoma technology, along with a panel of truncated mesothelin domain fragments, to identify anti-mesothelin mAbs that bind specific regions of mesothelin. In one aspect of the present disclosure, the rabbit mAbs bind an epitope that is not part of Region I. In particular, the identified mAbs (YP187, YP223, YP218 and YP3) bind either Region II (391-486), Region III (487-581) or a native conformation of mesothelin with subnanomolar affinity. These antibodies do not compete for binding with the mesothelin-specific immunotoxin SS1P or mesothelin-specific antibody MORAb-009. In another aspect, disclosed is a high-affinity rabbit mAb that binds Region I of mesothelin (YP158). YP158 binds native mesothelin protein in cancer cells and tissues with high affinity and specificity.

Abstract: The disclosure provides monoclonal bispecific antibodies targeting HER2 and HER3. The disclosure also provides monospecific tetravalent HER3 antigen binding antibodies. Still further provided by the disclosure are methods of treating a cancer in a subject, comprising administering to the subject a therapeutically effective amount of an antibody provided by the disclosure.

Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.

Abstract: The present inventors have completed the present invention by finding that an excellent anticoagulation inhibitory effect is obtained by the administration of an agent inhibiting the activation of protein C.

Abstract: The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.

Abstract: The present invention is directed to novel heterodimeric antibodies.

Abstract: Provided are exopolysaccharide produced by novel lactic acid bacteria having an IgA production promoting ability, a production method of the exopolysaccharide, a composition containing the exopolysaccharide, and the like.

Abstract: Provided herein are organic solvent-based processes for the removal of rubber from non-Hevea plants such as guayule shrubs. By the use of the processes, solid purified rubber can be obtained that contains 0.05-0.5 weight % dirt, 0.2-1.5 weight % ash, and 0.1-4 weight % resin (when it has been dried so as to contain 0.8 weight % volatile matter).

Abstract: Provided is a modified liquid diene-based rubber having an acryloyl group or a methacryloyl group, which is highly compatible with various monomers, such as acrylate or methacrylate having relatively high polarity, which can form a curable resin composition containing the modified liquid diene-based rubber with good workability, which has a satisfactory curing rate during curing, and which is capable of providing the curable resin composition that forms a cured product having excellent mechanical properties derived from the modified liquid diene-based rubber and having excellent adhesion to various materials. Also provided is a curable resin composition containing the modified liquid diene-based rubber.

Abstract: This invention provides a metallocene complex and the preparation method thereof and a catalyst composition. This catalyst composition comprises a metallocene complex represented by formula (I) and an organic boron salt. Compared to the prior art, the catalyst used in this invention, which is the metallocene complex represented by formula (I), does not contain any side chain, and the coordination space of the central metal has a large opening degree. Therefore, the catalytic activity for more sterically hindered monomers is higher, and the comonomer incorporation is also higher. Furthermore, the metallocene complex represented by formula (I) used in this invention is a heterocyclic ring fused cyclopentadienyl ligand. Heterocyclic rings have relatively strong electron-donating capacity. By fusing a cyclopentadienyl group using heterocyclic rings, it is possible to change the electronic effect of the metal center and in turn increase the activity of catalyst.

Abstract: A chemical composition, and formulated products selected from the group consisting of: hair conditioners, fabric softeners, skin moisturizers, shampoos, paper product additives, cosmetics, personal cleansing products, shave preparation products, detergents, non-woven additives, oral care products, and assembled products comprising treated paper or non-woven components, and comprising the chemical composition having the formula: R-C-Z-W wherein R comprises a hydrocarbon, C comprises a cyclic connector; Z comprises an amine; and W comprises a functional group, wherein functional group W is substantially free of oxygen in the instance where the cyclic connector, C, further comprises a carbonyl group.

Abstract: A solution polymerization process that consumes less energy comprising: injecting feeds into one or more reactors to form a polyethylene in a single liquid phase, or optionally two liquid phases; deactivating the single or dual liquid phase; a first V/L separator separates the deactivated phase into a first bottom stream and a first overhead stream; the first overhead stream passes to a distillation column and the first bottom stream enters a second V/L separator, forming a second overhead stream and a second bottom stream; the second bottom stream enters a third V/L separator, forming a third overhead stream and a third bottom stream; the third bottom stream passes to polymer recovery; the second and third overhead stream are combined, condensed and purified, forming a purified solvent that is recycled to said reactors.

Abstract: Disclosed are polyethylene, chlorinated polyethylene thereof and a molded article produced from the chlorinated polyethylene. More specifically, disclosed are polyethylene for preparation of chlorinated polyethylene, the polyethylene having a molecular weight distribution (MWD) of 5 or less, a melting index (5.0 kg) of 0.1 to 10 dg/min, a weight average molecular weight of 50,000 to 300,000 g/mol, a melting temperature of 125 to 135° C., a wax content of 0.0001 to 3% by weight or 0.01 to 0.3% by weight and a density of 0.94 g/cm3 or more, chlorinated polyethylene thereof and a molded article produced from the chlorinated polyethylene.

Abstract: The invention relates to a process for the preparation of a particulate ultra high molecular weight polyethylene (pUHMWPE copolymer, comprising the steps of preparing a magnesium containing carrier, loading the carrier with a organometallic compound forming a supported catalyst and contacting the supported catalyst with ethylene and at least one olefinic co-monomer under polymerization conditions, wherein the organometallic compound is of the formula R33P?N—TiCpXn.

Abstract: The present disclosure is directed to a process for producing olefin-based polymer in a gas phase polymerization reactor. The process includes forming a wet zone in the gas phase polymerization reactor. The wet zone is formed by maintaining a temperature less than or equal to the fluidizing medium dew point temperature+2° C. in a region of the reactor. The region is defined as the region extending from the distributor plate to 2.5 meters above the distributor plate. Injection of a high activity catalyst composition in the wet zone produces olefin-based having a settled bulk density greater than 23.5 lb/ft3.

Abstract: The invention relates to a process for converting hydrocarbons into products containing aldehydes and/or alcohols. The invention also relates to producing olefins from the aldehyde and alcohol, to polymerizing the olefins, and to equipment useful for these processes.

Abstract: An internal electron donor compound for preparing ?-olefin polymerization catalyst component, including two kinds of electron donors; the proportion of the two kinds of electron donors in the compounding preparation of the catalyst is determined via designed experiments so as to obtain a catalyst component having good comprehensive performance or a particular performance. The electron donor compound of the present invention can be used in the preparation of ?-olefin polymerization and co-polymerization catalyst component, particular the preparation of propylene polymerization catalyst component, and is applicable to prepare the propylene polymerization catalyst component by reacting magnesium chloride-ethanols complex compound carrier with titanium tetrachloride and electron donors, or to directly prepare the propylene polymerization catalyst component by reacting magnesium chloride, alcohols, titanium tetrachloride, and internal electron donor.

Abstract: Provided by the present invention is a vinyl alcohol polymer crosslinked by a structure represented by the following formula (1) and/or a disulfide structure, in which the vinyl alcohol polymer is not completely dissolved in a mixture prepared by: adding the vinyl alcohol polymer to water so as to give a concentration of 4% by mass; and stirring at 95° C. for 3 hrs. in the formula (1), R1, R2 and R3 each independently represent a hydrogen atom or a substituted or unsubstituted hydrocarbon group having 8 or less carbon atoms. Also provided include an additive for a drilling mud containing the vinyl alcohol polymer, a drilling mud containing the vinyl alcohol polymer as an additive, an additive for a drilling cement slurry containing the vinyl alcohol polymer, and a drilling cement slurry containing the vinyl alcohol polymer as an additive.

Abstract: The invention relates to a process for the manufacture of ?,?-branched carboxylic acids vinyl esters comprising the following steps: isomerising and converting an olefin feed with CO and water under Koch reaction conditions to make an acid with a ratio of Non Blocking isomers (NB) versus Blocking isomers (B) of NB/B above 1.5, wherein a blocking isomer has always a tertiary carbon atom in alpha position of the carboxylic acid and in the beta position of the carboxylic acid, whereas a non-blocking isomer has primary carbon atoms in the beta position of the carboxylic acid converting the resulting acid into a vinyl ester.

Abstract: The present subject matter relates to an amphiphilic reservoir protecting agent, including structural units denoted by the following formula (1), (2), (3) and (4). The present subject matter further provides a method for preparation of an amphiphilic reservoir protecting agent. The present subject matter further provides a drilling fluid that contains the amphiphilic reservoir protecting agent. The amphiphilic reservoir protecting agent and drilling fluid obtained in the present subject matter have high reservoir protection property and high shale inhibition property.

Abstract: The present invention provides a silicon-containing polymer which contains a repeating unit shown by the general formula (1-3) and one or more repeating units selected from repeating units shown by the general formulae (1-1) and (1-2) as a partial structure. There can be provided a composition for forming a silicon-containing resist under layer film, and a silicon-containing polymer and a silicon-containing compound to give the composition that is capable of forming a resist under layer film improved in adhesiveness in any resist pattern, regardless of negative development or positive development.

Abstract: A polymer comprising recurring units having an acid generator bound to the backbone, and recurring units having an optionally acid labile group-substituted carboxyl group and/or recurring units having an optionally acid labile group-substituted hydroxyl group is obtained by polymerizing corresponding monomers in a solution of a non-polymerizable compound containing a nitrogen atom to which an acid labile group is bound. This prevents deprotection reaction of the acid labile group in the case of positive resist-forming polymer or crosslinking reaction in the case of negative resist-forming polymer.

Abstract: Provided is a polycarbonate-modified acrylic resin obtained by reacting an unsaturated monomer mixture (B), which contains, as essential components, methyl methacrylate, an unsaturated monomer (b1) having a hydroxyl group, an unsaturated monomer (b2) having a carboxyl group, and an unsaturated monomer (b3) having an alkyl group of 2 to 8 carbon atoms, in the presence of a polycarbonate diol (A) which is produced using 1,5-pentanediol and 1,6-hexanediol as starting materials, characterized in that the mass ratio of the unsaturated monomer (b2) in the unsaturated monomer mixture (B) is in the range of 0.1% to 1.6% by mass. The polycarbonate-modified acrylic resin has high adhesion to a plastic substrate and is capable of forming a coating film having excellent abrasion resistance, chemical resistance, feel, and appearance. Therefore, the polycarbonate-modified acrylic resin can be suitably used for a coating.

Abstract: A photocurable composition according to the present invention comprising (A) a terminal-modified (hydrogenated) polybutadiene represented by formula [I]: (wherein R1 represents a hydrogen atom or a methyl group, R2 and R3 each independently represent a C1-C10 linear or branched alkylene group, a C3-C8 cycloalkylene group optionally substituted by a C1-C6 alkyl group, or a combination of the groups thereof, A represents a polymer chain obtained by polymerizing butadiene, or a polymer chain obtained by hydrogenating the former polymer chain thereof, and m represents 1 or 2) (B) a (meth)acrylic acid ester monomer, and (C) a photo-radical polymerization initiator.

Abstract: The present invention provides a method for producing a block copolymer, which includes subjecting styrene or a derivative thereof (excluding ?-methylstyrene) to living anionic polymerization in the presence of a polymerization initiator by means of a microreactor having a channel being capable of mixing a plurality of liquids with each other, reacting a propagation end of the resultant polymer block (A) derived from styrene or a derivative thereof with ?-methylstyrene to obtain an intermediate polymer having a polymer unit (B) derived from ?-methylstyrene bonded to one end of the polymer block (A), and then subjecting a)meth)acrylate compound (c) to living anionic polymerization in the presence of a polymerization initiator so that the polymer unit (B) derived from ?-methyl styrene in the intermediate polymer serves as a propagation end to form a polymer block (C) derived from the)meth)acrylate compound (c)